Aerosolized Capreomycin for Inhibition of Pulmonary Tuberculosis
Posted Feb 27 2011 7:00pm
Description of Invention: is technology involves the methods of reformulation of Capreomycin for the aerosol treatment of pulmonary tuberculosis.
Tuberculosis is a devastating lung disease that is highly infectious and easily transmitted, especially in areas of overcrowding such as prisons. Furthermore, underdeveloped countries with large populations living in close quarters maintain an endemic disease reservoir limiting the health and economic viability of the population. The WHO estimates that as many as 1/3 of the population may be infected. Current treatment requires the patient to take medication over an extended period of time, up to 12 months or more in some cases. This leads to clinical failure and the potential development of multi-drug resistant strains. Resistant strains of tuberculosis further tax the health care delivery as second line anti-tubercular therapies are more likely to have side effects yet still require long term adherence to therapy regimens.
The disclosed technology provides for the delivery of Capreomycin in an aerosol formulation. This provides for ease of delivery for in both first and second line tuberculosis regimens. Furthermore, the aerosol formulation does not require extensive training of health-care workers to administer the therapy, minimizing the need for added personnel in underdeveloped countries. This, along with the increased product stability will enhance patient adherence to therapy and the potential reduction of disease burden, both for the patient and the population.
Inventors: Carl N Kraus (NIAID) Bernard Doan (NIAID)
Portfolios: Infectious Diseases Infectious Diseases - Therapeutics Internal Medicine Internal Medicine - Therapeutics
For Licensing Information Please Contact: Kevin Chang Ph.D. NIH Office of Technology Transfer 6011 Executive Blvd. Suite 325, Rockville, MD 20852 United States Email: firstname.lastname@example.org Phone: 301-435-5018 Fax: 301-402-0220